The United States Patent and Trademark Office (USPTO) has granted patent US12582603B2 to NTC S.r.l. for an ophthalmic pharmaceutical composition. This patent specifically covers an aqueous composition containing a combination of brinzolamide and brimonidine, intended for reducing intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The composition includes a borate, a single polyol, and benzalkonium chloride as an antimicrobial agent, and the patent also details a method for its preparation.

This patent grant signifies a new intellectual property right for NTC S.r.l. regarding this specific ophthalmic formulation. While not a regulatory rule imposing obligations on other entities, it establishes exclusive rights for the patent holder. Companies operating in the pharmaceutical sector, particularly those developing or manufacturing ophthalmic treatments, should be aware of this patent to avoid potential infringement. No immediate compliance actions are required for other entities, but legal counsel should be consulted if developing similar compositions.